Clinical Trial Update: A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial) [Phase 4]

View source ↗

Summary

Phase 4 long-term trial evaluating dupilumab versus placebo for eosinophilic esophagitis, with 24 weeks of double-blind treatment followed by a 104-week open-la…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Sanofi | Conditions: Eosinophilic Oesophagitis | Phase 4 | Status: ACTIVE_NOT_RECRUITING